Reply: Lecanemab: turning point, or status quo? An ethics perspective

Brain. 2023 Sep 1;146(9):e73. doi: 10.1093/brain/awad102.

Authors

John Hardy^{1

2

3}, Catherine Mummery²

Affiliations

¹ Reta Lilla Weston Research Laboratories, UCL Institute of Neurology, London WC1N 3BG, UK.
² Department of Neurodegenerative Disease, UCL Institute of Neurology, London WC1N 3BG, UK.
³ Dementia Research Institute, UCL Institute of Neurology, London WC1N 3BG, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Alzheimer Disease*
Amyloidogenic Proteins
Decision Making
Humans

Substances

lecanemab
Amyloidogenic Proteins